Litcius/Paper detail

STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration

Jing Chen, Shuting Huang, Huawen Li, Yun Li, Haishan Zeng, Jiemei Hu, Yanchun Lin, Huihua Cai, Pengfei Deng, Ting Song, Tian Guan, Haoyu Zeng, Mubiao Liu

2022Clinical & Translational Oncology10 citationsDOI

Topics & Concepts

MedicineEndometrial cancerViability assayCancer researchCervical cancerCancerWestern blotOncologyCancer cellClinical trialCellInternal medicineBiologyGeneticsBiochemistryGeneCytokine Signaling Pathways and InteractionsCancer Cells and MetastasisImmune cells in cancer
STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration | Litcius